References in periodicals archive ?
Contract awarded for event 4286/15, bottle 35 mg agalsidase beta.
Also included are drug profiles for (migalastat hydrochloride + agalsidase alfa), agalsidase alfa, agalsidase beta biosimilar, Alpha-Galactosidase, Genz-682452, GZ-402671, JR-051, migalastat hydrochloride, Next Generation biologics for Pompe, Fabry and Hunter, NP-003, PRX-102 and Recombinant Enzyme to Replace Alpha-Galactosidase A for Fabry's Disease.
com) is studying the use in pregnancy of agalsidase beta (Fabrazyme) for Fabry disease.
Enzyme replacement therapy (ERT) with agalsidase alfa and agalsidase beta is available for the treatment of FD.
Renal outcomes of agalsidase beta treatmentfor Fabry disease: role of proteinuria and timing of treatment-initiation [published online ahead of print July 29, 2011].
Drug Profiles discussed in this report include (migalastat hydrochloride + agalsidase alfa), agalsidase alfa, agalsidase beta biosimilar, agalsidase beta biosimilar, Alpha-Galactosidase, Genz-682452, GZ-402671, JR-051, migalastat hydrochloride, Next Generation biologics for Pompe, Fabry and Hunter, NP-003, PRX-102, Recombinant Enzyme to Replace Alpha-Galactosidase A for Fabry's Disease.
2, ATC Code: A16AB04, Generic Name: Agalsidase beta, Pharmaceutical form: Pulv.
Contract awarded for ento 1782/2015 vial 35mg agalsidase beta.
Purified agalsidase beta is a homodimeric glycoprotein with a molecular weight of approximately 100 KD.